- Home
- GOCO vs ZNTL Comparison
GOCO vs ZNTL Comparison
Compare GOCO & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOCO
- ZNTL
- Stock Information
- Founded
- GOCO 2001
- ZNTL 2014
- Country
- GOCO United States
- ZNTL United States
- Employees
- GOCO N/A
- ZNTL N/A
- Industry
- GOCO Specialty Insurers
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- GOCO Finance
- ZNTL Health Care
- Exchange
- GOCO Nasdaq
- ZNTL Nasdaq
- Market Cap
- GOCO 111.2M
- ZNTL 102.2M
- IPO Year
- GOCO 2020
- ZNTL 2020
- Fundamental
- Price
- GOCO $7.39
- ZNTL $1.18
- Analyst Decision
- GOCO Hold
- ZNTL Buy
- Analyst Count
- GOCO 1
- ZNTL 8
- Target Price
- GOCO $13.00
- ZNTL $8.53
- AVG Volume (30 Days)
- GOCO 52.5K
- ZNTL 759.7K
- Earning Date
- GOCO 05-13-2025
- ZNTL 05-14-2025
- Dividend Yield
- GOCO N/A
- ZNTL N/A
- EPS Growth
- GOCO N/A
- ZNTL N/A
- EPS
- GOCO N/A
- ZNTL N/A
- Revenue
- GOCO $834,266,000.00
- ZNTL $67,425,000.00
- Revenue This Year
- GOCO $8.35
- ZNTL N/A
- Revenue Next Year
- GOCO $5.85
- ZNTL N/A
- P/E Ratio
- GOCO N/A
- ZNTL N/A
- Revenue Growth
- GOCO 13.18
- ZNTL N/A
- 52 Week Low
- GOCO $7.17
- ZNTL $1.01
- 52 Week High
- GOCO $21.00
- ZNTL $13.24
- Technical
- Relative Strength Index (RSI)
- GOCO 30.50
- ZNTL 37.05
- Support Level
- GOCO $7.35
- ZNTL $1.33
- Resistance Level
- GOCO $8.75
- ZNTL $1.33
- Average True Range (ATR)
- GOCO 0.85
- ZNTL 0.09
- MACD
- GOCO -0.06
- ZNTL -0.01
- Stochastic Oscillator
- GOCO 7.26
- ZNTL 2.74
About GOCO GoHealth Inc.
GoHealth Inc is a health insurance marketplace and Medicare-focused digital health company whose purpose is to compassionately ensure consumers' peace of mind when making healthcare decisions so consumers can focus on living life. It offers Medicare plans, including, but not limited to, Medicare Advantage, Medicare Supplement and prescription drug plans. Its proprietary technology platform leverages modern machine-learning algorithms, powered by over two decades of insurance purchasing behavior, to reimagine the process of matching a health plan to a consumer's specific needs.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.